Predicting Hospitalization, Exacerbation and Mortality in  Bronchiectasis Using Bronchiectasis Severity İndex and  FACED Scores

Bulut, Sertan; Çelik, Deniz; Karamanli, Harun

doi:10.14744/IGH.2022.02997

Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores

Sertan BULUT, (Ankara Atatürk Sanatevi Eğitimi ve Araştırma Hastanesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Harun KARAMANLI, (Ankara Atatürk Sanatevi Eğitimi ve Araştırma Hastanesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Deniz ÇELİK (Alanya Alaaddin Keykubat Üniversitesi Eğitimi ve Araştırma Hastanesi, Göğüs Hastalıkları Anabilim Dalı, Antalya, Türkiye)

İzmir Göğüs Hastanesi Dergisi

2 1

Yıl: 2022 Cilt: 36 Sayı: 2 Sayfa Aralığı: 77 - 85 Metin Dili: İngilizce DOI: 10.14744/IGH.2022.02997 İndeks Tarihi: 16-09-2022

Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores

Öz:

Objective: Bronchiectasis (BC) is a multifaceted and etiologically diverse condition and, as a result, no single endpoint can be used to determine its general severity and prognosis. Two different validated scores are currently being used to evaluate the seri ousness bronchiectasis: The bronchiectasis severity index (BSI) and the FACED score. It is aimed at comparing the bronchiectasis severity assessment questionnaires whichs are two different validated outcomes for mortality, exacerbation, and hospitalizations. Material and Methods: Medical records for 107 subjects with NCFB, for which BSI and FACED scores could be calculated, were reviewed retrospectively. The corre lations between the parameters and the BSI or FACED score were evaluated and a linear regression analysis was conducted to identify the independently associated variables of the BSI and FACED score. Results: The mean scores of FACED and BSI were 3.5±1.9 and 9.8±4.7, respectively. A statistically significant relationship was found between the FACED and BSI scores (p<0.0001), Pearson Chi-square (p=0.0001), and tau-b de Kendall (0.59; p=0.0001). It was showed a 60.7% similarity between the two scales by Kappa test (p<0.0001). BSI and FACED reported an area under ROC curve (AUC) for exacerbations of 0.758 and 0.755; and for hospitalizations (due to BE exacerbations) of 0.864 and 0.597, re spectively. The sensitivity of the BSI is higher (86% versus 59%) than the FACED rating. Conclusion: Patients tended to obtain a higher BSI score relative to the FACED score, although the correlation between the two scales was statistically significant. BSI is a helpful clinical predictor tool for identifying patients at risk of death, hos pitalization, and exacerbation in health-care systems.

Anahtar Kelime:

Bronşektazi Şiddeti İndeksi ve FACED Skorlaması Kullanılarak Bronşektazide Hastaneye Yatış, Alevlenme ve Mortalite Öngörüsü

Öz:

Amaç: Bronşektazi çok boyutlu ve etyolojik olarak farklı bir hastalıktır ve sonuç olarak, genel şiddetini ve prognozunu belirlemek için tek bir referans kullanılamaz. Bu çalışmada, mortalite, alevlenme ve hastaneye yatışlar için doğrulanmış iki farklı sonuç olan bronşek tazi şiddeti değerlendirme anketlerinin [Bronşektazi Şiddeti İndeksi (BSI) ve FACED] karşılaştırılması amaçlandı. Gereç ve Yöntemler: BSI ve FACED puanlarının hesaplanabildiği nonkistik fibrozis bronşektazili 107 denek için tıbbi kayıtlar geriye dönük olarak incelendi. Parametreler ile BSI veya FACED skoru arasındaki korelasyonlar değerlendirildi ve BSI ve FACED puanının bağımsız olarak ilişkili değişkenlerini tanımlamak için doğrusal bir regresyon analizi yapıldı. Bulgular: FACED ve BSI ortalama puanları sırasıyla 3,5±1,9 ve 9,8±4,7 olarak belirlendi. FACED ve BSI skorları arasında istatistiksel olarak anlamlı bir ilişki bulundu (p<0,0001). Pearson Chi-Square (p=0,0001), tau-b de Kendall (0,59; p=0,0001). Kappa testi ile iki ölçek arasında %60,7 benzerlik gösterildi (p<0,0001). Alevlenmeler için BSI ve FACED, 0,758 ve 0,755 ROC eğrisi (AUC) bir değer gösterdi; hastane yatışı için ise sırasıyla 0,864 ve 0,597 değerleri tespit edildi. BSI’nın duyarlılığı FACED derecelendirmesinden daha yüksektir (%86’ya karşı %59). Sonuç: İki ölçek arasındaki korelasyon istatistiksel olarak anlamlı olmasına rağmen, hastalar FACED skoruna göre daha yüksek bir BSI puanı alma eğilimindeydi. BSI, sağlık sistemlerinde ölüm, hastaneye yatış ve alevlenme riski olan hastaları tanımlamak için yararlı bir klinik tahmin aracıdır.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Pulmonology Portuguese Society Bronchiectasis Study Group. Recom mendations for aetiological diagnosis of bronchiectasis. Rev Port Pneu mol (2006) 2016;22:222–35.
2. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014;189:576–85.
3. Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010;138:944–9.
4. Restrepo M, Elborn JS. Bronchiectasis severity: Time to score. Am J Respir Crit Care Med 2014;189:508–9.
5. Martínez-García MÁ, de Gracia J, Vendrell Relat M, Girón RM, Máiz Carro L, de la Rosa Carrillo D, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: The FACED score. Eur Respir J 2014;43:1357–67.
6. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British thoracic society guideline for non-CF bronchiectasis. Thorax 2010;65(Suppl 1):i1–58.
7. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the medical research council working party. Lancet 1981;1:681–6.
8. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319–38.
9. Chalmers JD, McHugh BJ, Doherty C, Smith MP, Govan JR, Kilpatrick DC, et al. Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: A prospective study. Lancet Respir Med 2013;1:224–32.
10. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162:1277–84.
11. Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM. CT findings in bronchiectasis: Limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995;165:261–7.
12. McDonnell MJ, Aliberti S, Goeminne PC, Dimakou K, Zucchetti SC, Davidson J, et al. Multidimensional severity assessment in bronchiecta sis: An analysis of seven European cohorts. Thorax 2016;71:1110–8.
13. Ellis HC, Cowman S, Fernandes M, Wilson R, Loebinger MR. Predict ing mortality in bronchiectasis using bronchiectasis severity index and FACED scores: A 19-year cohort study. Eur Respir J 2016;47:482–9.
14. Martínez-García MA, Perpiñá-Tordera M, Soler-Cataluña JJ, Román Sánchez P, Lloris-Bayo A, González-Molina A. Dissociation of lung func tion, dyspnea ratings and pulmonary extension in bronchiectasis. Respir Med 2007;101:2248–53.
15. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the medical research council working party. Lancet 1981;1:681–6.
16. Martinez-Garcia MA, Athanazio RA, Girón R, Máiz-Carro L, de la Rosa D, Olveira C, et al. Predicting high risk of exacerbations in bronchiecta sis: The E-FACED score. Int J Chron Obstruct Pulmon Dis 2017;12:275– 84.
17. Athanazio R, Pereira MC, Gramblicka G, Cavalcanti-Lundgren F, de Figueiredo MF, Arancibia F, et al. Latin America validation of FACED score in patients with bronchiectasis: An analysis of six cohorts. BMC Pulm Med 2017;17:73.
18. Chalmers JD, McDonnell MJ, Rutherford R, Davidson J, Finch S, Crich ton M, et al. The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study. Respir Med 2016;112:51–8.

APA	Bulut S, Karamanli H, Çelik D (2022). Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores. , 77 - 85. 10.14744/IGH.2022.02997
Chicago	Bulut Sertan,Karamanli Harun,Çelik Deniz Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores. (2022): 77 - 85. 10.14744/IGH.2022.02997
MLA	Bulut Sertan,Karamanli Harun,Çelik Deniz Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores. , 2022, ss.77 - 85. 10.14744/IGH.2022.02997
AMA	Bulut S,Karamanli H,Çelik D Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores. . 2022; 77 - 85. 10.14744/IGH.2022.02997
Vancouver	Bulut S,Karamanli H,Çelik D Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores. . 2022; 77 - 85. 10.14744/IGH.2022.02997
IEEE	Bulut S,Karamanli H,Çelik D "Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores." , ss.77 - 85, 2022. 10.14744/IGH.2022.02997
ISNAD	Bulut, Sertan vd. "Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores". (2022), 77-85. https://doi.org/10.14744/IGH.2022.02997

APA	Bulut S, Karamanli H, Çelik D (2022). Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores. İzmir Göğüs Hastanesi Dergisi, 36(2), 77 - 85. 10.14744/IGH.2022.02997
Chicago	Bulut Sertan,Karamanli Harun,Çelik Deniz Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores. İzmir Göğüs Hastanesi Dergisi 36, no.2 (2022): 77 - 85. 10.14744/IGH.2022.02997
MLA	Bulut Sertan,Karamanli Harun,Çelik Deniz Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores. İzmir Göğüs Hastanesi Dergisi, vol.36, no.2, 2022, ss.77 - 85. 10.14744/IGH.2022.02997
AMA	Bulut S,Karamanli H,Çelik D Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores. İzmir Göğüs Hastanesi Dergisi. 2022; 36(2): 77 - 85. 10.14744/IGH.2022.02997
Vancouver	Bulut S,Karamanli H,Çelik D Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores. İzmir Göğüs Hastanesi Dergisi. 2022; 36(2): 77 - 85. 10.14744/IGH.2022.02997
IEEE	Bulut S,Karamanli H,Çelik D "Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores." İzmir Göğüs Hastanesi Dergisi, 36, ss.77 - 85, 2022. 10.14744/IGH.2022.02997
ISNAD	Bulut, Sertan vd. "Predicting Hospitalization, Exacerbation and Mortality in Bronchiectasis Using Bronchiectasis Severity İndex and FACED Scores". İzmir Göğüs Hastanesi Dergisi 36/2 (2022), 77-85. https://doi.org/10.14744/IGH.2022.02997